Henry Rodriguez

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Proteomics: a long and winding road to medical diagnostics
    Henry Rodriguez
    Director Clinical Proteomic Technologies for Cancer, Office of the Director, Office of Technology and Industrial Relations, National Cancer Institute, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA 1 301 496 1550
    Expert Opin Med Diagn 3:219-25. 2009
  2. ncbi Recommendations from the 2008 International Summit on Proteomics Data Release and Sharing Policy: the Amsterdam principles
    Henry Rodriguez
    Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Proteome Res 8:3689-92. 2009
  3. ncbi Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics
    Henry Rodriguez
    National Cancer Institute Food and Drug Administration Interagency Oncology Task Force on Molecular Diagnostics, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Chem 56:237-43. 2010
  4. ncbi Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proteomics 12:11-20. 2012
  5. ncbi Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States
    J Proteome Res 11:1412-9. 2012
  6. ncbi Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Cell Proteomics 10:O111.015446. 2011
  7. ncbi Restructuring proteomics through verification
    Emily Boja
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, NIH, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA
    Biomark Med 4:799-803. 2010
  8. ncbi The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science
    Emily S Boja
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Korean J Lab Med 31:61-71. 2011
  9. ncbi Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective
    Henry Rodriguez
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Proteomics Clin Appl 4:904-14. 2010
  10. ncbi Evolution of clinical proteomics and its role in medicine
    Emily Boja
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Proteome Res 10:66-84. 2011

Detail Information

Publications15

  1. ncbi Proteomics: a long and winding road to medical diagnostics
    Henry Rodriguez
    Director Clinical Proteomic Technologies for Cancer, Office of the Director, Office of Technology and Industrial Relations, National Cancer Institute, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA 1 301 496 1550
    Expert Opin Med Diagn 3:219-25. 2009
    ..If the potential of personalized medicine is to be realized, it needs to include this next generation of molecular diagnostics...
  2. ncbi Recommendations from the 2008 International Summit on Proteomics Data Release and Sharing Policy: the Amsterdam principles
    Henry Rodriguez
    Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Proteome Res 8:3689-92. 2009
    ..This summit report explores various approaches to develop a framework of data release and sharing principles that will most effectively fulfill the needs of the funding agencies and the research community...
  3. ncbi Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics
    Henry Rodriguez
    National Cancer Institute Food and Drug Administration Interagency Oncology Task Force on Molecular Diagnostics, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Chem 56:237-43. 2010
    ....
  4. ncbi Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proteomics 12:11-20. 2012
    ..The peer review process was a coordinated effort conducted by a panel of referees selected by the journals...
  5. ncbi Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States
    J Proteome Res 11:1412-9. 2012
    ..The peer review process was a coordinated effort conducted by a panel of referees selected by the journals...
  6. ncbi Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Cell Proteomics 10:O111.015446. 2011
    ..The peer review process was a coordinated effort conducted by a panel of referees selected by the journals...
  7. ncbi Restructuring proteomics through verification
    Emily Boja
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, NIH, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA
    Biomark Med 4:799-803. 2010
    ....
  8. ncbi The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science
    Emily S Boja
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Korean J Lab Med 31:61-71. 2011
    ....
  9. ncbi Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective
    Henry Rodriguez
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Proteomics Clin Appl 4:904-14. 2010
    ....
  10. ncbi Evolution of clinical proteomics and its role in medicine
    Emily Boja
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Proteome Res 10:66-84. 2011
    ..The availability of these multidimensional data to the scientific community sets the stage for the development of new molecularly targeted cancer interventions...
  11. ncbi Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins
    Emily S Boja
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proteomics 12:1093-110. 2012
    ....
  12. ncbi Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Proteomics Clin Appl 5:580-9. 2011
    ..The peer review process was a coordinated effort conducted by a panel of referees selected by the journals...
  13. ncbi A synopsis of the 3rd annual Cancer Proteomics Conference
    Mehdi Mesri
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD 20892, USA
    Expert Rev Proteomics 7:815-7. 2010
    ..Delegates had access to both meetings, allowing for enhanced interaction among investigators from the closely linked fields of research...
  14. ncbi AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development
    Samir N Khleif
    National Cancer Institute, Raritan, New Jersey, USA
    Clin Cancer Res 16:3299-318. 2010
    ....
  15. ncbi The journey to regulation of protein-based multiplex quantitative assays
    Emily S Boja
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Chem 57:560-7. 2011
    ..One key component in the biomarker development pipeline is the understanding of the regulatory science that evaluates diagnostic assay performance through rigorous analytical and clinical review criteria...